Esters of thienyl carboxylic acids and amino alcohols and their quaternization products

Abstract

Compounds of the formula ##STR1## of which, in exemplary compounds, the thienyl group is attached via the 2-position and:(a) A is 3.alpha.-(6.beta., 7.beta.-epoxy)-tropanyl methobromide and R.sub.1 is 2-thienyl;(b) A is 3.alpha.-(6, 7dehydro)-tropanyl methobromide and R.sub.1 is 2-thienyl;(c) A is 3.beta.-tropanyl methobromide and R.sub.1 is 2-thienyl; and,(d) A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide and R.sub.1 is cyclopentyl.These are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.

Description

The invention relates to novel thienylcarboxylates of amino alcohols and their quaternary products and to the preparation of the novel compounds and their use as active ingredients in medicaments.

The novel compounds correspond to the formula ##STR2## in which A represents the group ##STR3## wherein m and n independently of one another denote 1 or 2,

Q represents one of the double-bonding groups ##STR4## and Q' represents the group .dbd.NR or the group .dbd.NRR', wherein R denotes H or an optionally halogen-substituted or hydroxy-substituted C.sub.1 -C.sub.4 -alkyl radical, R' denotes a C.sub.1 -C.sub.4 -alkyl radical and R and R' together may also form a C.sub.4 -C.sub.6 -alkylene radical, and wherein, in the case of quaternary compounds, one equivalent of an anion (X.sup.-) opposes the positive charge of the N atom, R.sub.1 represents a thienyl, phenyl, furyl, cyclopentyl or cyclohexyl radical, wherein these radicals may also be methyl-substituted, thienyl and phenyl may also be fluoro-substituted or chloro-substituted, R.sub.2 represents hydrogen, OH, C.sub.1 -C.sub.4 -alkoxy or C.sub.1 -C.sub.4 -alkyl, R.sub.a represents H, F, Cl or CH.sub.3 and, if .dbd.NR denotes a secondary or tertiary amino group, also the acid addition salts.

In the compounds of formula I, R.sub.1 preferably represents thienyl, R.sub.2 preferably represents OH. The group --OA preferably has the .alpha.-configuration and is derived from, for example scopine, tropine, granatoline or 6,7-dehydrotropine or the corresponding nor-compounds; however, --OA may also have the .beta.-configuration, as in pseudotropine, pseudoscopine.

Corresponding radicals are, for example ##STR5##

The substituent R is preferably a lower alkyl radical, such as CH.sub.3, C.sub.2 H.sub.5, n-C.sub.3 H.sub.7, i-C.sub.3 H.sub.7, R' is preferably CH.sub.3. R and R' together are, for example --(CH.sub.2).sub.5 --. As halogen substituents for R, F or, as second choice, Cl are suitable.

If R denotes a halogen-substituted or hydroxy-substituted alkyl radical, it is preferably --CH.sub.2 --CH.sub.2 F or --CH.sub.2 --CH.sub.2 OH. Accordingly, the group A represents, for example the radicals of scopine, N-ethylnorscopine, N-isopropylnorscopine, tropine, N-isopropylnortropine, 6,7-dehydrotropine, N-.beta.-fluoroethylnortropine, N-isopropyl-6,7-dehydronortropine, N-methylgranatoline or the corresponding quaternary compounds, wherein the anion is preferably Br.sup.- or CH.sub.3 SO.sub.3.sup.-.

As the acid radical ##STR6## the following are particularly suitable: ##STR7##

The quaternary compounds are particularly suitable for therapeutic application, whereas the tertiary compounds are important not only as active ingredients but also as intermediate products.

The compounds of the invention are strong anti-cholinergic agents and have prolonged action. Action lasting at least 24 hours is achieved at inhaled dosages in the .mu.g range. In addition, the toxicity is in the same range as the commercial product Ipratropium bromide, while at the same time the therapeutic effect is stronger.

The novel compounds are suitable, in accordance with their anti-cholinergic nature, for example for the treatment of chronic obstructive bronchitis and (slight to moderately severe) asthma, also for the treatment of vagally induced sinus bradycardia.

Whereas application of the novel active ingredients (in particular the quaternary compounds) by inhalation is mainly recommended for respiratory tract diseases, as a result of which side-effects are largely eliminated, the application for sinus bradycardia is preferably carried out intravenously or orally. It has thus proved to be advantageous that the novel compounds leave the gastro/intestinal motility largely unaffected.

For administration the compounds of the invention are processed using known auxiliaries and/or excipients to give conventional galenic preparations, for example inhalation solutions, suspensions in liquified propellants, preparations containing liposomes or proliposomes, injection solutions, tablets, coated tablets, capsules, inhalation powders for use in conventional inhalation apparatus.

Formulation examples (measures in weight per cent):

______________________________________1. Controlled dosage aerosol______________________________________Active ingredient according to the invention 0.005Sorbitan trioleate 0.1monofluorotrichloromethane and to 100Difluorodichloromethane 2:3______________________________________

The suspension is poured into a conventional aerosol container with a dosage valve. 50 .mu.l of suspension are preferably dispensed per actuation. The active ingredient may also be metered in a higher amount if required (for example 0.02 wt. %).

______________________________________2. Tablets______________________________________Active ingredient according to the invention 0.05Colloidal silicic acid 0.95Lactose 65.00Potato starch 28.00Polyvinylpyrrolidone 3.00Na cellulose glycolate 2.00Magnesium stearate 1.00______________________________________ The constituents are processed in conventional manner to give tablets of 200 mg.

The advantageous properties of the novel compounds are shown, for example, in the inhibition of broncholysis in the rabbit (acetylcholine spasms intravenously). After intravenous administration of the novel active ingredients (dosage 3 .mu.g/kg intravenously), the maximum effect occurred after 10 to 40 minutes. After 5 hours the inhibiting effect had still not been reduced to half, that is to say the half effect time is more, in some cases considerably more, than 5 hours, as made clear by the residual effects after 5 hours listed below:

__________________________________________________________________________ Compound Residual effect in %__________________________________________________________________________ A 76 B 76 C 81 D 61 E 68 F 73 G 69__________________________________________________________________________Compounds of the formula ##STR8##Compound A R.sub.1__________________________________________________________________________ ##STR9## 2-thienylB ##STR10## 3-thienylD ##STR11## 2-thienylE ##STR12## 3-thienylF ##STR13## cyclopentylG ##STR14## cyclopentyl Compound C ##STR15##__________________________________________________________________________ Notes: 1. The compounds in which R.sub.1 is not 2thienyl are racemates. 2. The compounds are 3.alpha.-compounds in each case. Processes known per se are used to prepare the novel compounds.

An ester of the formula ##STR16## wherein R" represents a C.sub.1 -C.sub.4 -alkyl radical, preferably a methyl or ethyl radical (R.sub.1, R.sub.2 and R.sub.a have the above meanings), is preferably transesterified using an amino alcohol of the formula ##STR17## wherein m, n and Q have the above meanings, Q" represents .dbd.NR or .dbd.NH and the OH group is in the .alpha.- or .beta.-position, in the presence of a conventional transesterification catalyst, and the compound obtained is optionally quaternised

a) if Q" denotes .dbd.NR (R.notident.H) , using a reactive mono-functionalised derivative Z-(C.sub.1 -C.sub.4 -alkyl) of a corresponding alkane (Z=leaving group) or is optionally quaternised b) if Q" denotes .dbd.NH, using a terminally disubstituted alkane Z-(C.sub.4 -C.sub.6 -alkylene)-Z without isolation of intermediates.

The transesterification is carried out with heat in an organic solvent, for example toluene, xylene, heptane, or in a melt, strong bases such as sodium methylate, sodium ethylate, sodium hydride, metallic sodium, being used as catalyst. Reduced pressure is used to remove the released lower alcohol from the equilibrium, the alcohol is optionally distilled off azeotropically. The transesterification takes place at temperatures which in general do not exceed 95.degree. C. Transesterification often proceeds more favourably in a melt. If required, the free bases may be obtained in a manner known per se from acid addition salts of the tertiary amines using suitable basic compounds. Quaternisation is carried out in suitable solvents, for example acetonitrile or acetonitrile/methylene chloride, preferably at room temperature; a corresponding alkyl halide, for example alkyl bromide, is preferably used in the process as quaternising agent. Transesterification products wherein Q' represents NH are used as starting materials for those compounds in which R and R' together represent a C.sub.4 -C.sub.6 -alkylene group. Conversion into the tertiary and then quaternary compound then takes place with the aid of suitable 1,4-dihaloalkanes, 1,5-dihaloalkanes or 1,6-dihaloalkanes without isolation of intermediates.

The starting materials may be obtained analogously to known compounds--in as much as they have not already been described.

EXAMPLES

methyl di-(2-thienyl)glycolate from dimethyl oxalate and 2-thienyl magnesium bromide; ethyl di-(2-thienyl)glycolate from (2-thienyl)glyoxylic acid and 2-thienyl lithium; ethyl hydroxy-phenyl-(2-thienyl)acetate from methyl phenylglyoxylate and 2-thienyl magnesium bromide or from methyl (2-thienyl)glyoxylate and phenyl magnesium bromide. Methyl 2-thienylglyoxylate and cyclohexyl or cyclopentyl magnesium bromide may be reacted in a similar manner.

Several processes are also available for the preparation of the amino alcohols.

Pseudoscopine may be obtained in accordance with M. Polonovski et al., Bull. soc. chim. 43, 79 (1928). Pseudotropenol may be removed from the mixture (fractional crystallisation or distillation) which is obtained, for example in accordance with V. Hayakawa et al., J. Amer. Chem. Soc. 1978, 100(6), 1786 or R. Noyori et al., J. Amer. Chem. Soc. 1974, 96(10), 3336.

The corresponding methyl esters may be prepared in a conventional manner starting from 2-furylglyoxylnitrile or 3-furylglyoxylnitrile via the 2-furylglyoxylic acid or 3-furylglyoxylic acid which can be obtained therefrom. The corresponding glycolates are obtained from these as described using the organometallic derivatives of 2-bromothiophene or 3-bromothiophene. The organometallic compounds which can be obtained from 2-, 3- or 4-halopyridine can be reacted with methyl 2-thienylglyoxylate or methyl 3-thienylglyoxylate to give the corresponding glycolates.

Thienylglycolates, in which the thiophene ring contains fluorine in the 2- or 3-position, are prepared, for example starting from 2-fluorothiophene or 3-fluorothiophene (bromination to give 2-bromo-3-fluorothiophene or 2-bromo-5-fluorothiophene), and after conversion to the corresponding organometallic compounds, reaction with suitable glyoxylates to give the glycolates.

2-Fluorothiophene and 3-fluorothiophene can be reacted analogously to give the corresponding glyoxylates Unterhalt, Arch. Pharm. 322, 839 (1989) which in turn, as already described, may be reacted with, for example 2-thienyl or 3-thienyl derivatives, to give glycolates. Symmetrically substituted di-thienylglycolates can be prepared analogously by selecting suitable components.

A further route is available via a process analogous to the benzoin condensation and benzilic acid rearrangement.

The following examples illustrate the invention without limiting it.

EXAMPLE 1

EXAMPLE 1

Scopine di-(2-thienyl)glycolate

50.87 g (0.2 mole) of methyl di-(2-thienyl)glycolate and 31.04 g (0.2 mole) of scopine are dissolved in 100 ml of absolute toluene and reacted at a bath temperature of 90.degree. C. with addition of 1.65 g (0.071 gram atom) of sodium in several portions. The resulting methanol is distilled off at a reaction mixture temperature of 78.degree.-90.degree. C. under a pressure of 500 mbar. After a reaction time of about 5 hours, the reaction mixture is stirred into a mixture of ice and hydrochloric acid. The acid phase is separated off, rendered alkaline using sodium carbonate and the free base is extracted using methylene chloride. After drying over sodium sulphate, the methylene chloride is distilled off under reduced pressure and the residue is recrystallised from acetonitrile; beige-coloured crystals (from acetonitrile),

m.p. 149.degree.-50.degree. C.,

Yield: 33.79 g (44.7% of theoretical).

EXAMPLE 2

Scopine di-(2-thienyl)glycolate

12.72 g (0.05 mole) of methyl di-(2-thienyl)glycolate and 7.76 g (0.05 mole) of scopine are melted in a heating bath at 70.degree. C. under a water jet vacuum. 2.70 g (0.05 mole) of sodium methylate are introduced into this melt and heated for 1 hour in a heating bath at 70.degree. C. under a water jet vacuum and subsequently for a further hour in a heating bath at 90.degree. C. The solidified melt is taken up in a mixture of 100 ml of water and 100 ml of methylene chloride while monitoring the temperature, and the methylene chloride phase is extracted several times using water. The methylene chloride phase is extracted using the corresponding amount of dilute hydrochloric acid. The scopine di-(2-thienyl)glycolate is extracted from the combined aqueous phases using methylene chloride after adding the corresponding amount of sodium carbonate and dried over sodium sulphate. The hydrochloride is prepared from the dried methylene chloride solution in a conventional manner. The crystals are filtered off under suction, washed using acetone and dried under reduced pressure at 35.degree. C. Pale yellow crystals (from methanol), m.p. 238.degree.-41.degree. C. (decomposition);

Yield: 10.99 g (53.1% of theoretical).

The hydrochloride may be converted to the base in a conventional manner.

EXAMPLE 3

Scopine di-(2-thienyl)glycolate

38.15 g (0.15 mole) of methyl di-(2-thienyl)glycolate and 23.28 g (0.15 mole) of scopine are mixed, 0.34 g (0.015 gram atom) of sodium is added and the mixture is melted in a heating bath at 90.degree. C. under a water jet vacuum. The reaction lasts 2.5 hours. 100 ml of absolute toluene are then added and the mixture is stirred at a heating bath temperature of 90.degree. C. until a solution is produced. The reaction solution is cooled to room temperature and stirred into a mixture of ice and hydrochloric acid cooled using ice. The hydrochloride of the basic ester crystallising out is filtered off under suction and washed using a small amount of water and a large amount of diethyl ether. The filtrate phases are separated off and the aqueous phase is extracted using diethyl ether. The hydrochloride filtered off under suction is suspended in the (acid) aqueous phase and converted to the base while monitoring the temperature and adding the corresponding amount of sodium carbonate; the base is extracted using methylene chloride. The combined methylene chloride phases are dried over sodium sulphate. After distilling off the methylene chloride, crystals remain which are purified over active charcoal and recrystallised from acetonitrile. Pale yellow crystals (from acetonitrile), m.p. 148.degree.-49.degree. C.;

Yield: 39.71 g (70.1% of theoretical).

TABLE I______________________________________Compounds of the formula ##STR18## M.p. [.degree.C.] Hydro-No. A R.sub.1 Base chloride______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-thienyl 149-50 238-412 3.alpha.-tropanyl 2-thienyl 167-8 2533 3.alpha.-(6,7-dehydro)-tropanyl 2-thienyl 164-54 3.alpha.-(N-.beta.-fluoroethyl)- 2-thienyl 236 nortropanyl5 3.alpha.-(N-isopropyl)- 2-thienyl 232 granatanyl6 3.alpha.-(N-isopropyl)- 2-thienyl 256 nortropanyl7 3.alpha.-(6.beta.,7.beta.-epoxy)-N- 2-thienyl 206 isopropyl-nortropanyl8 3.alpha.-(6.beta.,7.beta.-epoxy)-N-ethyl- 2-thienyl 212-3 nortropanyl9 3.alpha.-(N-ethyl)-nortropanyl 2-thienyl 256-710 3.alpha.-(N-N-methyl)- 2-thienyl 241 granatanyl11 3.alpha.-(6.beta.,7.beta.-epoxy)-N-.beta.- 2-thienyl 188-90 fluoroethylnortropanyl12 3.alpha.-(6.beta.,7.beta.-epoxy)-N-n- 2-thienyl 104-6 propylnortropanyl13 3.alpha.-(6.beta.,7.beta.-epoxy)-N-n- 2-thienyl 225-7 butylnortropanyl14 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl phenyl 246-715 3.alpha.-tropanyl phenyl 243-416 3.alpha.-(N-.beta.-fluoroethyl)- phenyl 219-20 nortropanyl17 3.alpha.-(6,7-dehydro)-tropanyl phenyl 181-318 3.alpha.-(N-ethyl)-nortropanyl phenyl 231-219 3.alpha.-(N-isopropyl)- phenyl 246-7 nortropanyl20 3.alpha.-tropanyl cyclo- 260 hexyl21 3.alpha.-(N-.beta.-fluoroethyl)- cyclo- 203-4 nortropanyl hexyl22 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl cyclo- 237 pentyl23 3.alpha.-tropanyl cyclo- 260 pentyl24 3.alpha.-(N-.beta.-fluoroethyl)- cyclo- 182-3 nortropanyl pentyl25 3.alpha.-(N-ethyl)-nortropanyl cyclo- 227-8 pentyl26 3.alpha.-(N-isopropyl)- cyclo- 174-5 nortropanyl pentyl27 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-thienyl 240-228 3.beta.-tropanyl 2-thienyl 217-929 3.beta.-(6,7-dehydro)-tropanyl 2-thienyl 233-530 3.alpha.-(6,7-dehydro)-trapanyl 3-thienyl 247-831 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 3-thienyl 242-332 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-furyl33 3.alpha.-(6,7-dehydro)-tropanyl 2-furyl34 3.alpha.-tropanyl 2-furyl35 3.alpha.-tropanyl 2-pyridyl36 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-pyridyl37 3.alpha.-(6,7-dehydro)-tropanyl 2-pyridyl38 3.alpha.-tropanyl 3-thienyl39 3.alpha.-(6,7-dehydro)-tropanyl cyclo- pentyl40 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl cyclo- hexyl41 3.alpha.-(6,7-dehydro)-tropanyl cyclo- hexyl______________________________________ Note: All hydrochlorides melt with decomposition.

EXAMPLE 4

Scopine di-(2-thienyl)glycolate methobromide

10.0 g (0.0265 mole) of scopine di-(2-thienyl)glycolate are dissolved in a mixture comprising 20 ml of anhydrous methylene chloride and 30 ml of anhydrous acetonitrile and treated with 12.8 g (0.1325 mole) of methyl bromide (as 50% strength solution in anhydrous acetonitrile), and the reaction mixture is allowed to stand for 24 hours at room temperature in a tightly sealed reaction vessel. Crystals are precipitated during this time. They are filtered off under suction, washed using methylene chloride and dried at 35.degree. C. under reduced pressure. White crystals (from methanol/acetone), m.p. 217.degree.-8.degree. C. (decomposition) after drying at 111.degree. C. under reduced pressure.

TABLE II______________________________________Quaternary compounds of the formula ##STR19##No. A R.sub.1 M.p. [.degree.C.]______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-thienyl 217-18 methobromide2 3.alpha.-tropanyl methobromide 2-thienyl 263-643 3.alpha.-(6,7-dehydro)-tropanyl 2-thienyl 191-92 methobromide4 3.alpha.-(N-.beta.-fluoroethyl)- 2-thienyl 242-43 nortropanylmethobromide5 3.alpha.-tropanyl-.beta.- 2-thienyl 214-15 fluoroethobromide6 3.alpha.-(N-isopropyl)- 2-thienyl 229-30 granatanyl methobromide7 3.alpha.-(N-isopropyl)- 2-thienyl 245-46 nortropanylmethobromide8 3.alpha.-(6.beta.,7.beta.-epoxy)-N- 2-thienyl 223-24 isopropyl-nortropanyl methobromide9 3.alpha.-(6.beta.,7.beta.-epoxy)-N- 2-thienyl 215-16 ethylnortrapanyl methobromide10 3.alpha.-(N-ethyl)-nortropanyl 2-thienyl 260-61 methobromide11 3.alpha.-(N-methyl)-granatanyl- 2-thienyl 246-47 methobromide12 3.alpha.-(6.beta.,7.beta.-epoxy)-N- 2-thienyl 182-83 fluoroethyl- nortropanyl methobromide13 3.alpha.-(6.beta.,7.beta.-epoxy)-N-n- 2-thienyl 209-10 propylnortropanyl methobromide14 3.alpha.-tropanyl-.beta.- 2-thienyl 231-32 hydroxyethobromide15 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl phenyl 217-18 ethobromide16 3.alpha.-tropanyl methobromide phenyl 273-7417 3.alpha.-(N-.beta.-fluoroethyl)- phenyl nortrapanylmethobromide18 3.alpha.-(6,7-dehydro)-tropanyl phenyl 110-71 methobromide19 3.alpha.-(N-ethyl)-nortropanyl phenyl 249-50 methobromide20 3.alpha.-(N-isopropyl)- phenyl 259-60 nortropanyl methobromide21 3.alpha.-tropanyl ethobromide phenyl 248-4922 3.alpha.-(N-ethyl)-nortropanyl phenyl 244-45 ethobromide23 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl phenyl 226 ethobromide24 3.alpha.-tropanyl-.beta.- phenyl 241 fluoroethobromide25 3.alpha.-tropanyl methobromide cyclohexyl 27826 3.alpha.-(N-.beta.-fluoroethyl)- cyclohexyl 198 nortropanyl methobromide27 3.alpha.-tropanyl-.beta.- cyclohexyl 233-34 fluoroethobromide28 3.alpha.-tropanyl methobromide cyclopentyl 26029 3.alpha.-tropanyl ethobromide cyclopentyl 235-3630 3.alpha.-(N-ethyl)-nortropanyl cyclopentyl 251-52 methobromide31 3.alpha.-(N-isopropyl)- cyclopentyl 244-45 nortropanyl-methobromide32 3.alpha.-tropanyl-.beta.- cyclopentyl 189-90 fluoroethobromide33 3.alpha.-(N-.beta.-fluoroethyl)- cyclopentyl 226-27 nortropanyl-methobromide34 3.alpha.-(6,7-dehydro)-tropanyl 2-thienyl 225-6 metho-methanesulphonate35 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-thienyl 218-20 methobromide36 3.alpha.-tropanyl methobromide 2-thienyl 243-437 3.alpha.-(6,7-dehydro)-tropanyl 2-thienyl 211-4 methobromide38 3.alpha.-(6,7-dehydro)-tropanyl 3-thienyl 182-3* methobromide39 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 3-thienyl 217-8 methobromide40 (+) enantiomer of No. 141 (-) enantiomer of No. 142 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-furyl methobromide43 3.alpha.-(6,7-dehydro)-tropanyl 2-furyl methobromide44 3.alpha.-tropanyl methobromide 2-furyl45 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-pyridyl methobromide46 3.alpha.-(6,7-dehydro)-tropanyl 2-pyridyl methobromide47 3.alpha.-tropanyl methobromide 2-pyridyl48 3.alpha.-tropanyl methobromide 3-thienyl49 3.alpha.-(6,7-dehydro)-tropanyl cyclopentyl methobromide50 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl cyclohexyl methobromide51 3.alpha.-(6,7-dehydro)-tropanyl cyclohexyl methobromide52 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl cyclopentyl methobromide______________________________________ *contains crystalline methanol Note: All compounds in the table melt with decomposition. TABLE III______________________________________Compounds of the formula ##STR20## M.p. [.degree.C.]No. A R.sub.1 Hydrochloride______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl phenyl 246-72 3.alpha.-(6,7-dehydro)-tropanyl phenyl 261-23 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 3-thienyl4 3.alpha.-(6,7-dehydro)-tropanyl 3-thienyl5 3.alpha.-tropanyl 3-thienyl6 3.alpha.-(N-methyl)-granatanyl 3-thienyl______________________________________ TABLE IV______________________________________Compounds of the formula ##STR21## M.p. [.degree.C.]No. A R.sub.2 Hydrochloride______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl H2 3.alpha.-(6,7-dehydro)-tropanyl H3 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl methyl4 3.alpha.-(6,7-dehydro)-tropanyl methyl 210-2.55 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl methoxy6 3.alpha.-(6,7-dehydro)-tropanyl methoxy______________________________________ TABLE V______________________________________Compounds of the formula ##STR22## M.p.No. A R.sub.2 R.sub.a [.degree.C.]______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tro- 2-thienyl 5-methyl panyl2 3.alpha.-(6,7-dehydro)-tro- 2-thienyl 5-methyl panyl3 3.alpha.-tropanyl 2-thienyl 5-methyl4 3.alpha.-(6.beta.,7.beta.-epoxy)-tro- 2-(5-methyl)- 5-methyl panyl thienyl5 3.alpha.-(6,7-dehydro)-tro- 2-(5-methyl)- 5-methyl panyl thienyl6 3.alpha.-tropanyl 2-(5-methyl)- 5-methyl thienyl7 3.alpha.-(6.beta.,7.beta.-epoxy)-tro- 2-thienyl 5-fluoro panyl8 3.alpha.-(6,7-dehydro)-tro- 2-thienyl 5-fluoro panyl9 3.alpha.-tropanyl 2-thienyl 5-fluoro10 3.alpha.-(6.beta.,7.beta.-epoxy)-tro- 2-(5-fluoro)- 5-fluoro panyl thienyl11 3.alpha.-(6,7-dehydro)-tro- 2-(5-fluoro)- 5-fluoro panyl thienyl12 3.alpha.-tropanyl 2-(5-fluoro)- 5-fluoro thienyl______________________________________ TABLE VI__________________________________________________________________________Compounds of the formula ##STR23##No. A R.sub.1 R.sub.a M.p. [.degree.C.]__________________________________________________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-thienyl 5-methyl methobromide2 3.alpha.-(6,7-dehydro)-tropanyl 2-thienyl 5-methyl methobromide3 3.alpha.-tropanyl-methobromide 2-thienyl 5-methyl4 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-(5-methyl)- 5-methyl methobromide thienyl5 3.alpha.-(6,7-dehydro)-iropanyl 2-(5-methyl)- 5-methyl methobromide thienyl6 3.alpha.-tropanyl methobromide 2-(5-methyl)- 5-methyl thienyl7 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-thienyl 5-fluoro methobromide8 a-(6,7-dehydro)-tropanyl 2-thienyl 5-fluoro methobromide9 3.alpha.-tropanyl methobromide 2-thienyl 5-fluoro10 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 2-(5-fluoro)- 5-fluoro methobromide thienyl11 3.alpha.-(6,7-dehydro)-tropanyl 2-(5-fluoro)- 5-fluoro methobromide thienyl12 3.alpha.-tropanyl methobromide 2-(5-fluoro)- 5-fluoro thienyl__________________________________________________________________________ TABLE VII______________________________________Compounds of the formula ##STR24##No. A R.sub.1 M.p. [.degree.C.]______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl phenyl 211-2 methobromide2 3.alpha.-(6,7-dehydro)-tropanyl phenyl 158-60* methobromide3 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl 3-thienyl methobromide4 3.alpha.-(6,7-dehydro)-tropanyl 3-thienyl methobromide5 3.alpha.-tropanyl methobromide 3-thienyl6 3.alpha.-(N-methyl)-granatanyl 3-thienyl methobromide______________________________________ *(with crystalline methanol) TABLE VIII______________________________________Quaternary compounds of the formula ##STR25##No. A R.sub.2 M.p. [.degree.C.]______________________________________1 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl H methobromide2 3.alpha.-(6,7-dehydro)-tropanyl H methobromide3 3.alpha.-(6.beta.,7.beta.-epoxy)-tropanyl methyl methobromide4 3.alpha.-(6,7-dehydro)-tropanyl methyl 206-8 methobromide5 3.alpha.-tropanyl methobromide methoxy6 3.alpha.-(N-methyl)-tropanyl methoxy methobromide______________________________________

Claims

1. A compound of the formula ##STR26## wherein Q is a group of the formula --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or ##STR27## R and R' are each independently C.sub.1 -C.sub.4 -alkyl; R.sub.1 is thienyl, phenyl, cyclopentyl or cyclohexyl; and,

X.sup.- is a physiologically acceptable anion.

2. A compound in accordance with claim 1, of the formula ##STR28## wherein R is CH.sub.3, C.sub.2 H.sub.5, n-C.sub.3 H.sub.7, or i-C.sub.3 H.sub.7 ;

R' is CH.sub.3 ; and,

R.sub.1, Q and X.sup.- are as defined in claim 1.

3. A compound in accordance with claim 2 wherein R.sub.1 is thienyl.

4. A compound in accordance with claim 2 wherein X.sup.- is Br.sup.- or CH.sub.3 SO.sub.3.

5. A compound of the formula ##STR29## wherein X.sup.- is a physiologically acceptable anion.

6. A compound of the formula ##STR30## wherein X.sup.- is a physiologically acceptable onion.

7. A compound of the formula ##STR31##

8. A compound of the formula ##STR32## wherein R.sub.1 is 2-thienyl and A is 3.alpha.-(6,7-dehydro)-tropanyl methobronide.

9. A compound of the formula ##STR33## wherein R.sub.1 is 2-thienyl and A is 3.beta.-tropanyl methobromide.

10. A compound of the formula ##STR34## wherein R.sub.1 is cyclopentyl and A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide.

11. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4 6, 7, 8, 9, 10.

12. A method for treating slight to moderately severe asthma which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

13. A method for treating vagally induced sinus bradycardia which comprises administering, by the intravenous or oral routes, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

14. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

15. A pharmaceutical composition, for oral administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.

16. A pharmaceutical composition, for intravenous administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10.